aspartylglutamate has been researched along with Leukemia, Myeloid, Acute in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alexe, G; Back, M; Benajiba, L; Campbell, AJ; Conway, A; DeAngelo, DJ; Gale, JP; Galinsky, I; Hemann, MT; Hermine, O; Holson, EB; Kaya, T; Kung, A; Lakshminarasimhan, D; Machleidt, T; Pan, JQ; Pikman, Y; Puissant, A; Robers, MB; Ross, L; Sacher, JR; Scolnick, E; Shi, X; Stegmaier, K; Stein, AJ; Stone, RM; Wagner, FF; Weïwer, M; Wilkinson, J; Zhang, YL | 1 |
1 other study(ies) available for aspartylglutamate and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia.
Topics: beta Catenin; Dipeptides; Enzyme Inhibitors; Glycogen Synthase Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutagenesis, Site-Directed; Protein Isoforms; U937 Cells | 2018 |